CION Ameerpet
ALCL is a rare, CD30-positive T-cell lymphoma. Whether the tumour is ALK-positive or ALK-negative shapes both treatment and outlook. This guide explains the subtypes clearly and how CION's haematology team plans care.
Anaplastic large cell lymphoma (ALCL) is a rare type of T-cell lymphoma — a non-Hodgkin lymphoma that develops from mature T-lymphocytes, one of the immune system's key cell types. Under the microscope its cells are large and abnormal ("anaplastic"), and they characteristically carry the CD30 marker on their surface. CD30 is so consistently present that it has become a defining feature of the diagnosis.
The single most important thing to understand about systemic ALCL is its ALK status. Many cases carry a rearrangement of the ALK gene — these ALK positive lymphoma cases tend to occur in younger people and generally carry a more favourable outlook. Cases without this change (ALK-negative) are more common in older adults and, on average, behave more aggressively. Alongside CD30 and ALK, pathologists map the tumour's other markers to reach a precise diagnosis.
This guide walks through the different forms of ALCL, explains why CD30 and ALK matter, and sets out how the disease is diagnosed and treated. For the full picture of lymphoma care, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page. If you would like your reports reviewed, book a free consultation with our team.
The name "anaplastic large cell lymphoma" comes from the large, unusual cells seen under the microscope — but its defining fingerprint is the CD30 marker, present on virtually all ALCL cells. CD30 is not just a diagnostic clue; it is also a treatment target, which is why antibody therapy directed at CD30-bearing cells is an established option for these lymphomas. (Source: WHO Classification of Haematolymphoid Tumours, as referenced in NCCN and ESMO T-cell lymphoma guidelines.)
ALCL is not one disease but a family of related lymphomas. They share the CD30 marker, yet behave very differently — which is why an exact diagnosis on biopsy matters so much.
| Type | Who it affects | Typical behaviour | General approach |
|---|---|---|---|
| Systemic ALK-positive | Often children & younger adults | Aggressive but responsive; generally more favourable outlook | Combination chemotherapy ± CD30-directed antibody therapy |
| Systemic ALK-negative | More common in older adults | More variable, often more aggressive on average | Combination chemotherapy ± antibody therapy; transplant considered for high-risk cases |
| Primary cutaneous ALCL | Adults, skin-limited | Usually indolent; excellent long-term outlook | Localised radiation or watch-and-wait monitoring |
| Breast implant-associated (BIA-ALCL) | People with textured breast implants | Often localised; frequently curable when caught early | Surgery to remove implant & capsule |
Behaviour and outcomes vary by individual; this table is a general guide. Subtyping is decided by a haematopathologist on tissue, using CD30 and ALK testing, following the WHO classification and NCCN/ESMO guidance.
Symptoms depend on which form of ALCL is present and where it is. Systemic disease often behaves quite quickly, so signs that appear and worsen over weeks deserve prompt review.
Painless, enlarging lumps in the neck, armpit or groin are the most common presentation of systemic ALCL. Unlike a passing infection, these do not settle after a couple of weeks.
Unexplained fever, drenching night sweats and unintended weight loss together are called B symptoms. They are common in systemic ALCL and always warrant investigation.
In cutaneous forms, one or more firm skin nodules or lumps may appear, sometimes ulcerating. Primary cutaneous ALCL is usually slow-growing and skin-limited.
In BIA-ALCL, fluid collection, swelling or a mass around a textured breast implant — often years after surgery — is the typical sign and should be assessed promptly.
These signs have many ordinary causes, and most are not lymphoma. But anything new, persistent and progressive should be checked. Speak to a CION specialist if you have these signs or a confirmed ALCL diagnosis.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received an ALCL diagnosis, want to understand what your ALK status and CD30 result mean, or need a second opinion before treatment? CION's haematology team is here.
Diagnosing ALCL — and pinning down its exact type and ALK status — takes a step-by-step pathway. CION delivers the biopsy coordination, immunohistochemistry, staging scans and bone-marrow assessment directly, with every case reviewed by a multidisciplinary tumour board.
Only a tissue sample can confirm ALCL. Usually this is an excisional or core biopsy of an affected lymph node, or a skin biopsy for cutaneous disease. A haematopathologist examines the cells and their architecture. A blood test or scan alone cannot make this diagnosis.
On the tissue, immunohistochemistry confirms strong, uniform CD30 expression. The tumour is then tested for ALK protein or ALK gene rearrangement (using techniques such as FISH) to separate ALK-positive from ALK-negative disease. Additional markers map the other T-cell proteins. These molecular tests are not optional extras — per NCCN and ESMO, CD30 and ALK status should be established before treatment is finalised, because they define both the subtype and the outlook.
Once ALCL is confirmed, a PET-CT scan maps how far the lymphoma has spread, and a bone-marrow examination is often done to complete staging. Together these set the stage and guide the intensity of treatment. CION performs staging and bone-marrow assessment in-house.
The treatment plan depends on the type, ALK status, stage and your overall health, and is set by CION's multidisciplinary tumour board. The main building blocks are below. For specific regimens and drug combinations, see our Lymphoma Treatment in Hyderabad page.
Systemic ALCL is generally treated with combination chemotherapy — several drug classes given together in cycles. CION's medical oncology team delivers systemic therapy directly, with supportive care to manage side effects. ALK-positive disease tends to respond particularly well.
Because ALCL cells carry the CD30 marker, an anti-CD30 antibody-based therapy is an established, targeted approach that is often combined with chemotherapy. This is delivered directly by CION under specialist supervision. The exact combination is individualised to your subtype and stage.
For localised disease — including primary cutaneous ALCL and some early-stage systemic disease — precision radiation (IMRT) may be used, delivered in-house. It shapes the beam to the affected area while sparing healthy tissue.
For high-risk or relapsed systemic ALCL, a stem-cell transplant may be considered. CION coordinates this through accredited partner facilities and manages the referral and surrounding care; it is not delivered in-house.
Breast implant-associated ALCL is usually treated with surgery to remove the implant and surrounding capsule, and is often curable when found early. Selected indolent cutaneous cases may be carefully monitored with a watch-and-wait approach rather than treated immediately.
ALCL is one of the more treatable T-cell lymphomas, and the outlook depends heavily on the type and ALK status. ALK-positive systemic ALCL generally carries a favourable prognosis, with published series reporting 5-year survival often in the region of 70–90%, particularly in younger patients. ALK-negative systemic ALCL is more variable and, on average, less favourable — though outcomes have improved with CD30-directed treatment. Primary cutaneous ALCL has an excellent long-term outlook, and early-stage BIA-ALCL is frequently curable with surgery alone.
These figures are drawn from published series (as summarised in NCCN and ESMO guidance) and vary considerably by individual — your own outlook depends on the subtype, stage, treatment response and general health. A specialist can explain what the numbers mean for your situation.
To understand where ALCL sits within the wider disease and how it is managed, explore related pages: peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma and lymphoblastic lymphoma.
An ALCL diagnosis carries a lot of nuance, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service, with care from our best lymphoma doctors in Hyderabad at our lymphoma hospital in Hyderabad. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's tumour board — especially valuable if CD30 and ALK testing has not yet been confirmed on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Anaplastic large cell lymphoma (ALCL) is a rare type of T-cell lymphoma — a non-Hodgkin lymphoma that develops from mature T-lymphocytes. Its cells are large and unusual (anaplastic) and typically carry the CD30 marker on their surface, which is a defining diagnostic feature. ALCL can appear in lymph nodes and, in some forms, in the skin. It accounts for only a small share of all lymphomas, but it is one of the more treatable T-cell subtypes, especially when the tumour cells carry a rearrangement of the ALK gene. Accurate subtyping on a tissue biopsy is essential because the different forms of ALCL behave and are managed differently. For the wider picture, see the Lymphoma hub.
Systemic ALCL is divided by whether the tumour cells carry a rearrangement of the ALK gene. ALK-positive lymphoma tends to occur in younger people, including children and young adults, and generally carries a more favourable outlook. ALK-negative ALCL is more common in older adults and, on average, behaves more aggressively — though molecular features can refine this picture further. Both are tested for on the biopsy tissue by immunohistochemistry and, where needed, genetic techniques such as FISH. Knowing the ALK status is central to planning treatment and estimating prognosis, which is why NCCN and ESMO guidelines make ALK testing a standard part of the diagnostic work-up for ALCL.
There are several distinct forms of ALCL, and they behave very differently. Systemic ALK-positive ALCL and systemic ALK-negative ALCL involve lymph nodes and internal organs. Primary cutaneous ALCL is confined to the skin, is usually indolent, and is part of the same family as other cutaneous T-cell lymphomas. Breast implant-associated ALCL (BIA-ALCL) is a separate, rare form that arises in the fluid or capsule around a textured breast implant and is generally treatable with surgery when caught early. Because outlook and treatment differ so much between these types, an exact diagnosis on biopsy — including CD30 and ALK testing — is essential.
CD30 is a protein found on the surface of ALCL cells, and by definition it is strongly and uniformly expressed in this lymphoma. It has two important roles. First, it is a diagnostic marker — pathologists use CD30 staining on the biopsy, alongside ALK testing, to confirm ALCL and distinguish it from other T-cell lymphomas. Second, CD30 is a treatment target: antibody-based therapy directed against CD30-bearing cells is an established approach for CD30-positive lymphomas, delivered under specialist supervision. Because CD30 is central to both diagnosis and therapy, it is routinely tested on ALCL tissue. Specific regimen and drug choices are individualised — discuss these on our Lymphoma Treatment in Hyderabad page.
Diagnosis rests on a tissue biopsy — usually an excisional or core biopsy of an affected lymph node or skin lesion — examined by a haematopathologist. The tissue is tested for CD30 (which is positive in ALCL) and for ALK protein or ALK gene rearrangement to separate ALK-positive from ALK-negative disease. Additional immunohistochemistry maps the other T-cell markers. Staging then uses a PET-CT scan and often a bone-marrow examination to see how far the lymphoma has spread. CION performs biopsy coordination, immunohistochemistry, staging scans and bone-marrow assessment directly, and every case is reviewed by a multidisciplinary tumour board. NCCN and ESMO both recommend confirming CD30 and ALK status before treatment is finalised.
Treatment depends on the type, ALK status, stage and your general health, and is set by CION's multidisciplinary tumour board. Systemic ALCL is generally treated with combination chemotherapy, often together with CD30-directed antibody therapy, both delivered directly by CION's medical oncology team. Radiation therapy (IMRT) may be added for localised disease. For high-risk or relapsed systemic ALCL, a stem-cell transplant may be considered and is coordinated through accredited partner facilities — CION manages the referral and the surrounding care. Primary cutaneous ALCL is often managed with localised radiation or a watch-and-wait approach, while BIA-ALCL is usually treated with surgery to remove the implant and capsule. For specific regimens, see Lymphoma Treatment in Hyderabad.
ALCL is one of the more treatable T-cell lymphomas, and outlook depends heavily on the type and ALK status. ALK-positive systemic ALCL generally carries a favourable prognosis, with published series reporting 5-year survival often in the region of 70–90%, particularly in younger patients. ALK-negative systemic ALCL is more variable and, on average, less favourable, though outcomes have improved with CD30-directed treatment. Primary cutaneous ALCL has an excellent long-term outlook, and early-stage BIA-ALCL is often curable with surgery alone. These figures are drawn from published series and vary by individual — your own outlook depends on stage, response and health. A specialist can explain what the numbers mean for you; book a free consultation to discuss.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.